2000
DOI: 10.1046/j.1442-2042.2000.00231.x
|View full text |Cite
|
Sign up to set email alerts
|

Prostate cancer with multiple lung metastases in a hemodialysis patient

Abstract: In hemodialysis patients, few cases of prostate cancer have been reported until recently. We present a case of prostate cancer with multiple lung metastases in a chronic hemodialysis patient. A 65-year-old Japanese man who had maintained hemodialysis for 5 years was referred to our hospital with multiple metastatic lung tumors. Serum prostate tumor markers were highly elevated although his plasma testosterone level was within the normal range. A transrectal needle prostate biopsy confirmed a histologic diagnos… Show more

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
2
1

Citation Types

0
3
0

Year Published

2001
2001
2017
2017

Publication Types

Select...
5

Relationship

0
5

Authors

Journals

citations
Cited by 5 publications
(3 citation statements)
references
References 13 publications
0
3
0
Order By: Relevance
“…This may be in part due to lower use of PSA screening in the ESRD population, demonstrated both in this study and in previous work (8,9). In addition, the absence of urinary output may hinder early diagnosis on the basis of urinary tract symptoms (22). Despite the poor outcome in distant disease, it is still unclear whether PSA screening reduces mortality in the general population (23).…”
Section: Discussionmentioning
confidence: 99%
“…This may be in part due to lower use of PSA screening in the ESRD population, demonstrated both in this study and in previous work (8,9). In addition, the absence of urinary output may hinder early diagnosis on the basis of urinary tract symptoms (22). Despite the poor outcome in distant disease, it is still unclear whether PSA screening reduces mortality in the general population (23).…”
Section: Discussionmentioning
confidence: 99%
“…so-called stage migration [1]. However, most patients with ESRD and prostate cancer have advanced prostate cancer, even after the advent of PSA testing [15].…”
Section: Discussionmentioning
confidence: 99%
“…There are several confounding factors which may affect the diagnosis and evaluation of cancer in ESRD such as delayed symptomatic presentation, a non-validated and unclear utility of tumor markers, dilemmas in imaging studies, and lack of prognostic data. Several important cancer presentations may be omitted in ESRD such as hypercalcemia, hyperphosphatemia, pruritus, anemia with severity inadequate to the kidney function and oliguria/anuria [ 118 ]. Serum cancer antigen 125 (CA-125) may be a useful tumor marker however, it can be elevated in ascites, even in non-malignant settings [ 119 ].…”
Section: Introductionmentioning
confidence: 99%